Statement from Wondfo Biotech, following the Indian Council of Medical Research (ICMR) Advisory on Rapid Antibody Blood Tests
April 28,2020 (Edit) Wondfo
It is with regret that we read the ICMR’s ‘Advisory on Rapid Antibody Blood Tests’ to stop using test kits procured from us and another supplier.
 
The Wondfo SARS-CoV-2 Antibody Test (Lateral Flow Method) is one of the first tests to receive an import license from India, and has been validated and approved by the ICMR through National Institute of Virology (NIV), Pune. As a company, quality is our highest priority and we are confident in the quality of our products which meet standards in China and countries that we are exporting to.
 
We are currently investigating the ICMR’s concerns with our products.
 
Wondfo has been and will continue to be transparent about the measures we are taking to ensure the supply and the accuracy of our tests and that our products meet the needs of countries as we collectively combat COVID-19.
 
 
 
Guangzhou Wondfo Biotech Co., Ltd.
 
April 28th, 2020